The rise of artificial intelligence (A.I.) in the pharmaceutical industry signifies a transformative period, placing unprecedented power in the hands of tech-driven drug discovery and igniting debates about innovation, control, and patient safety. Subject to regulatory scrutiny, the FDA has
In a significant move reflecting the growing regulatory pressure on data security practices, Enzo Biochem has reached a settlement with the Attorneys General of Connecticut, New York, and New Jersey over allegations of inadequate security measures leading to a data breach earlier this year. The
Employee turnover in the biopharma industry has reached unprecedented levels in recent years, causing a significant threat to intellectual property (IP) security. As the sector grapples with layoffs and recruitment shifts, there is an increasing need to understand how these workforce changes impact
Omnichannel marketing has been heralded as the next frontier in customer engagement, offering a seamless and integrated experience across various channels. The biopharmaceutical industry is no stranger to this trend, with a significant number of the top 100 pharmaceutical companies adopting
In the ever-evolving landscape of pharmaceuticals, the debate over regulatory data protection (RDP) is intensifying. As the Belgian Presidency of the Council of the EU approaches its twilight, policymakers are grappling with how to balance the imperatives of fostering pharmaceutical innovation with
The European Health Data Space (EHDS) marks a significant shift in healthcare within the European Union, profoundly affecting the management and usage of health data. It promises to empower EU citizens with better control over their health information while also improving clinical practices. The
